Skip to content
‹ Back to IndustriesSciences

How Are AI Pros Weighing ChatGPT’s Role in the World of Science?

New evolving and fast-developing AIs have started rising to fame in recent years, and with the recent invention of ChatGPT – an AI chatbot launched in late 2022 which gained over 100 million users within the first two months of launching – people from all around the world are starting to question the role of AI technology…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By carey.scott · · AiChat GptDeveloping AiScience
Share

Key takeaways

01

New evolving and fast-developing AIs have started rising to fame in recent years, and with the recent invention of ChatGPT – an AI chatbot launched in late 2022 which gained over 100 million users within the first two months of launching – people from all around the world are starting to question the role of AI technology…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

New evolving and fast-developing AIs have started rising to fame in recent years, and with the recent invention of ChatGPT – an AI chatbot launched in late 2022 which gained over 100 million users within the first two months of launching – people from all around the world are starting to question the role of AI technology in their daily lives. Among these uncertainties is ChatGPT’s role in the world of science.

Will there be a huge impact of ChatGPT and developing AI in science? How will Chat GPT and developing AI contribute to modern science?

Biologists like Casey Greene and Milton Pividori see the tool as incredibly useful. After running their own research of using the tool for improving the quality and readability of academic manuscripts, Pividori concluded that ChatGPT, alongside other AI tools, is adding value to their lives by making helping scientists be “more productive as researchers.”

Meanwhile, other scientists are saying that they now regularly use LLMs (large language models like ChatGPT) not only to edit manuscripts but also to help them write or check code and to brainstorm ideas. As Nature.com reports, scientists like Almira Osmanovic Thunström, a neurobiologist at Sahlgrenska University Hospital in Gothenburg, says the use of ChatGPT will keep scientists from needing to “sit and write long introductions for grant applications.”

That being said, many scientists and researchers have pointed out a few disadvantages of AI tools. These are in the form of inaccurate information and fictitious citations presented by AI machines, giving scientists a reason to rely less on AI and more on their own manual research and cross-referencing. Can researchers confidently pinpoint ChatGPT’s role in the world of science?

Ganesh Gopalan, CEO and co-founder of Gnani.ai, a conversational AI platform with a focus on customer experience enhancement, weighs in on the impact of ChatGPT and other developing AI tools in the world of science and the difference it can make in research fields.

Ganesh Gopalan’s Thoughts

“ChatGPT is going to help researchers automate all their routine activities such as writing publications, reviewing documents are automatically creating extracts.

These articles typically warn of the pitfalls in terms of biases that ChatGPT could throw up and the possible inaccuracies. So, what I thought the best thing to evaluate this is to ask ChatGPT the same question. When I ask ChatGPT the same questions, I got a lot more results such as the influence on drug discovery, the influence on analyzing large pieces of scientific data and finding the relationships.

So essentially, I guess ChatGPT has a lot of benefits for science but you’ve gotta be a little careful on the biases and also on the accuracy of the data.”

Article written by Azam Saghir.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

C
carey.scott
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

C
carey.scott

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512